Improving treatment results with reference centres for rare cancers: Where do we stand?

European Journal of Cancer

Volumn 77, Issue , 2017, Pages 90-98

  Ray Coquard, Isabelle ^a   Pujade Lauraine, Eric ^b   Le Cesne, Axel ^c   Pautier, Patricia ^c   Vacher Lavenue, Marie Cecile ^b   Trama, Annalisa ^d   Casali, Paolo ^d   Coindre, Jean Michel ^e   Blay, Jean Yves ^a  

^a CENTRE LÉON BÉRARD   (France)

^b ASSISTANCE PUBLIQUE HÔPITAUX DE PARIS   (France)

^c INSTITUT GUSTAVE ROUSSY   (France)

^d NATIONAL CANCER INSTITUTE   (Italy)

^e INSTITUT BERGONIÉ   (France)

Author keywords

Cancer network; Cancer Reference centre; Rare cancer; Survival

Indexed keywords

CANCER CENTER; CANCER EPIDEMIOLOGY; CANCER SURVIVAL; CLINICAL TRIAL (TOPIC); EUROPEAN UNION; FEMALE GENITAL TRACT TUMOR; HEALTH CARE ORGANIZATION; HUMAN; MALIGNANT NEOPLASM; OVARY CANCER; PRIORITY JOURNAL; RARE DISEASE; REVIEW; SARCOMA; TREATMENT OUTCOME; ADULT; EPIDEMIOLOGY; EUROPE; FEMALE; HEALTH CARE PLANNING; INTERNATIONAL COOPERATION; MALE; MORTALITY; MOTIVATION; NEOPLASMS; PATIENT CARE; PATIENT REFERRAL; RARE DISEASES;

ADULT; CANCER CARE FACILITIES; CLINICAL TRIALS AS TOPIC; EPIDEMIOLOGIC METHODS; EUROPE; EUROPEAN UNION; FEMALE; GOALS; HEALTH PLANNING; HEALTH PLANNING ORGANIZATIONS; HUMANS; INTERNATIONAL COOPERATION; MALE; NEOPLASMS; PATIENT CARE TEAM; RARE DISEASES; REFERRAL AND CONSULTATION;

EID: 85016490571     PISSN: 09598049     EISSN: 18790852     Source Type: Journal    
DOI: 10.1016/j.ejca.2017.02.006     Document Type: Review

References (19)

1. [1] Ferrari, A., Trama, A., De, P.A., Bergeron, C., Merks, J.H., Jenney, M., et al. Access to clinical trials for adolescents with soft tissue sarcomas: enrollment in European pediatric Soft tissue sarcoma Study Group (EpSSG) protocols. Pediatr Blood Cancer, 10, 2016 November 24.
2. [2] Blay, J.Y., Coindre, J.M., Ducimetiere, F., Ray-Coquard, I., The value of research collaborations and consortia in rare cancers. Lancet Oncol 17:2 (2016 February), e62–e69.
3. [3] Gatta, G., van der Zwan, J.M., Casali, P.G., Siesling, S., Dei Tos, A.P., Kunkler, I., et al. Rare cancers are not so rare: the rare cancer burden in Europe. Eur J Cancer 47:17 (2011 November), 2493–2511.
4. [4] Gatta, G., Capocaccia, R., Trama, A., Martinez-Garcia, C., The burden of rare cancers in Europe. Adv Exp Med Biol 686 (2010), 285–303, 10.1007/978-90-481-9485-8_17.:285–303.
5. [5] Mallone, S., de, A.R., van der Zwan, J.M., Trama, A., Siesling, S., Gatta, G., et al. Methodological aspects of estimating rare cancer prevalence in Europe: the experience of the RARECARE project. Cancer Epidemiol 37:6 (2013 December), 850–856.
6. [6] Gatta, G., Ciccolallo, L., Kunkler, I., Capocaccia, R., Berrino, F., Coleman, M.P., et al. Survival from rare cancer in adults: a population-based study. Lancet Oncol 7:2 (2006 February), 132–140.
7. [7] Francisci, S., Minicozzi, P., Pierannunzio, D., Ardanaz, E., Eberle, A., Grimsrud, T.K., et al. Survival patterns in lung and pleural cancer in Europe 1999–2007: results from the EUROCARE-5 study. Eur J Cancer, 15, 2015 September 5, 10.
8. [8] Ray-Coquard, I., Le, C.A., A role for maintenance therapy in managing sarcoma. Cancer Treat Rev 38:5 (2012 Aug), 368–378.
9. [9] van der Graaf, W.T., Blay, J.Y., Chawla, S.P., Kim, D.W., Bui-Nguyen, B., Casali, P.G., et al. Pazopanib for metastatic soft-tissue sarcoma (PALETTE): a randomised, double-blind, placebo-controlled phase 3 trial. Lancet 379:9829 (2012 May 19), 1879–1886.
10. [10] Harbeck, N., Gnant, M., Breast cancer. Lancet 16 (2016 November 16), 10–6736.
11. [11] Ray-Coquard, I., Ledermann, J., International Journal of Gynecological Cancer. Editorial. Int J Gynecol Cancer 24:9 Suppl 3 (2014 November), S2–S4.
12. [12] Ray-Coquard, I., Pujade-Lauraine, E., Ledermann, J.A., New clinical research strategies for rare gynecologic malignancies. Curr Opin Obstet Gynecol 27:1 (2015 February), 53–57.
13. [13] Keat, N., Law, K., McConnell, A., Seymour, M., Welch, J., Trimble, T., et al. International Rare Cancers Initiative (IRCI). Ecancermedicalscience, 7, 2013 May 21, ed20, 10.3332/ecancer.2013.ed20 eCollection;%2013.:ed20.
14. [14] Chan, J.K., Teoh, D., Hu, J.M., Shin, J.Y., Osann, K., Kapp, D.S., Do clear cell ovarian carcinomas have poorer prognosis compared to other epithelial cell types? A study of 1411 clear cell ovarian cancers. Gynecol Oncol 109:3 (2008 June), 370–376.
15. [15] Grinding to a halt: the effects of the increasing regulatory burden on research and quality improvement efforts. Clin Infect Dis 49:3 (2009 August 1), 328–335.
16. [16] Bogaerts, J., Sydes, M.R., Keat, N., McConnell, A., Benson, A., Ho, A., et al. Clinical trial designs for rare diseases: studies developed and discussed by the International Rare Cancers Initiative. Eur J Cancer 51:3 (2015 February), 271–281.
17. [17] Penel, N., Coindre, J.M., Bonvalot, S., Italiano, A., Neuville, A., Le, C.A., et al. Management of desmoid tumours: a nationwide survey of labelled reference centre networks in France. Eur J Cancer 58 (2016 May), 90–96.
18. [18] Heudel, P.E., Cousin, P., Lurkin, A., Cropet, C., Ducimetiere, F., Collard, O., et al. Territorial inequalities in management and conformity to clinical guidelines for sarcoma patients: an exhaustive population-based cohort analysis in the Rhone-Alpes region. Int J Clin Oncol 19:4 (2014 Aug), 744–752.
19. [19] Blay, J.Y., Derbel, O., Ray-Coquard, I., The clinician's perspective on sarcoma pathology reporting: impact on treatment decisions?. Pathology 46:2 (2014 February), 121–125.